Predictive OncologyPOAI
POAI
About: Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Employees: 35
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
26% more capital invested
Capital invested by funds: $157K [Q3] → $197K (+$40.6K) [Q4]
6% more funds holding
Funds holding: 17 [Q3] → 18 (+1) [Q4]
0.58% more ownership
Funds ownership: 3.03% [Q3] → 3.61% (+0.58%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for POAI.
Financial journalist opinion
Based on 3 articles about POAI published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024.
Neutral
GlobeNewsWire
1 week ago
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan
Neutral
GlobeNewsWire
1 week ago
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Deal positions STREAMWAY ® Systems with an established market leader to drive accelerating growth
Neutral
GlobeNewsWire
1 month ago
Predictive Oncology Closes Registered Direct Offering
PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules.
Neutral
GlobeNewsWire
1 month ago
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing
Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types
Neutral
Business Wire
1 month ago
Certis Oncology Announces Issuance of U.S. Patent for Its Proprietary CertisAI Predictive Oncology Intelligence™ Platform
SAN DIEGO--(BUSINESS WIRE)-- #CertisAI--Certis Oncology Solutions, a precision oncology and translational science company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application directed to Certis's predictive artificial intelligence/machine learning (AI/ML) platform, CertisAI™. “The patent marks an important milestone for our company,” said Peter Ellman, President and CEO of Certis. “It substantiates the uniqueness of our proprietary platform and the un.
Neutral
Business Wire
2 months ago
AIRNA Appoints Matthew Hawryluk as Chief Business Officer
CAMBRIDGE, Mass. & TÜBINGEN, Germany--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a proven track record of bridging scientific innovation and commercial application. “Matt is a tremendous addition to our leadership team, bringi.
Neutral
GlobeNewsWire
2 months ago
Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay
Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe and expanded availability in the United States. The ChemoFx® treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time.
Neutral
Business Wire
2 months ago
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive.
Neutral
Business Wire
2 months ago
POAI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Predictive Oncology Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Predictive Oncology Inc. (NASDAQ: POAI) to Renovaro Inc. is fair to Predictive shareholders. Halper Sadeh encourages Predictive shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Predictive and its board of direct.
Charts implemented using Lightweight Charts™